Kelonia Therapeutics brings to Eli Lilly an in vivo cell therapy in early clinical development for multiple myeloma. The deal complements Lilly’s acquisitions of Verve Therapeutics and Orna Therapeutics in the past year, each taking different approaches to developing in vivo genetic medicines. The post Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition appeared first on MedCity News .
OSHA and NIOSH recommend that all hospitals develop comprehensive violence prevention programs. Here are some action items that provide a framework for building a legally defensible program. The post OSHA’s Evolving Approach to Workplace Violence Prevention in Healthcare appeared first on MedCity News .
When patients disengage, preventive care is missed, chronic conditions worsen, care shifts to higher-cost settings such as the emergency department and urgent care, and patients fragment across systems, reducing continuity. The post Stopping Patient Attrition Before it Starts: A Proactive Approach to Healthcare Marketing appeared first on MedCity News .
Himanshu Shah, an activist investor and large shareholder of Novavax, whose stock has plummeted over the years, believes the company should cut costs more aggressively, reduce the size of its board, and do more to prop up its financial performance. But are the criticisms valid? The post Is Shah Capital’s Criticism of Novavax Fair? A Wall Street Analyst Weighs In appeared first on MedCity News .
Obsidian Therapeutics aims to show its TIL cell therapy has advantages over an Iovance Biotherapeutics TIL therapy marketed for treating melanoma. Obsidian’s merger with Galera Therapeutics will give it a public listing and a private placement to support clinical development of the combined company’s cancer drug pipeline. The post Obsidian, Galera Merger Comes With $350M Infusion for Cancer Drug Trials appeared first on MedCity News .
CMS is proposing to make its joint replacement bundled payment model mandatory nationwide. Experts say it is a logical step, but warn that mandatory participation could be challenging for hospitals to implement. The post Expanding the CJR Model Is a Logical Step in VBC, but Implementation Challenges Remain appeared first on MedCity News .
Care delivery doesn’t have to be binary — in-person or virtual, old model or new. It can be adaptive, team-based, and deeply human. The post How Team-Based and Virtual Nursing Models Are Redefining Care Delivery appeared first on MedCity News .
The challenge isn’t whether AI can be used (it already is). It’s whether it can be trusted. And trust in medicine is not something healthcare professionals can afford to get wrong. The post Trust and AI Adoption in Medicine appeared first on MedCity News .
A new report from Trilliant Health finds behavioral health demand has surged since 2018, but workforce shortages and access barriers continue to limit care. The post Behavioral Health Demand Has Increased by 62% Since 2018. What the Industry Needs to Know appeared first on MedCity News .
Kailera Therapeutics’ IPO proceeds will support global clinical trials for its obesity drug candidates. Meanwhile, proteomics company Alamar Biosciences upsized its own IPO while clinical-stage biotechs Seaport Therapeutics and Hemab Therapeutics joined the IPO queue. The post Kailera’s Upsized IPO Brings In $625M for Pipeline of Injectable & Oral Obesity Drugs appeared first on MedCity News .